<p>Seer, Inc. ((SEER)) 举行了第三季度财报电话会议。以下是会议的主要亮点。</p>
<h3>认识你的 ETF 人工智能分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> 人工智能分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> 人工智能分析师</strong> 对你关注的 ETF 的洞察。</li>
</ul>
<p>Seer, Inc. 最近的财报电话会议描绘了成就与挑战并存的局面。公司展示了其 Proteograph 平台的强劲需求、创纪录的出版物数量以及战略合作伙伴关系。然而，增长幅度温和，政府停摆和市场不确定性对客户预算和销售周期造成了影响。</p>
<h2>创纪录的出版物数量</h2>
<p>公司实现了创纪录的第三方出版物数量，突显了 Proteograph 的价值。这一成就进一步验证了该平台在多种应用中的表现，增强了其信誉和市场地位。</p>
<h2>仪器出货量增加</h2>
<p>Seer 报告称仪器出货量显著增加，2025 年前九个月的出货量几乎是 2024 年全年出货量的三倍。这一激增反映了对 Proteograph 的强劲需求，突显了其在市场上的日益普及。</p>
<h2>与韩国大学的大规模研究</h2>
<p>Seer 与韩国大学开展了一项大规模研究，涉及 20,000 个样本，同时还与 Discovery Life Sciences 开展了一个 10,000 个样本的项目。这些举措展示了该平台处理大规模研究项目的能力，可能带来重大的科学进展。</p>
<h2>高客户参与度</h2>
<p>Proteograph ONE 检测和 SP200 自动化仪器获得了客户的极大好评。发布后初期观察到的强劲需求和使用情况表明市场进入成功，客户满意度高。</p>
<h2>与 Thermo Fisher 的首次联合销售</h2>
<p>公司在与 Thermo Fisher 的合作中取得了进展，成功实现了首次联合销售。这一发展标志着合作的良好开端，可能为增长和创新开辟新的途径。</p>
<h2>股票回购计划</h2>
<p>Seer 积极参与股票回购计划，回购了约 2200 万美元的 A 类普通股。这一举措使得净流通股总数减少了约 14%，反映了公司对其财务健康和未来前景的信心。</p>
<h2>收入增长微弱</h2>
<p>尽管取得了一些成就，Seer 报告称收入增长微弱，同比仅增长 2%，达到 410 万美元。这一温和增长突显了当前经济环境中面临的挑战，特别是由于外部因素如政府政策的影响。</p>
<h2>政府停摆带来的挑战</h2>
<p>政府停摆带来了重大挑战，导致预算和资金可用性的不确定性。这种情况影响了公司的运营和财务表现，迫使其进行战略调整。</p>
<h2>销售周期延长</h2>
<p>Seer 正经历销售周期延长，主要是由于资本支出预算的压力以及政府停摆对 NIH 资金的影响。这为销售过程增加了复杂性，影响了收入实现的时间表。</p>
<h2>持续的市场不确定性</h2>
<p>由于持续的市场不确定性，公司预计收入将在指导范围的下半部分。政府资金限制和客户预算限制继续带来挑战，影响财务预测。</p>
<h2>前瞻性指导</h2>
<p>尽管面临挑战，Seer 对未来保持乐观。公司以强劲的资产负债表结束了本季度，持有约 2.51 亿美元的现金、现金等价物和投资。预计全年收入将在 1700 万美元到 1800 万美元之间，尽管政府资金的不确定性和停摆的潜在影响可能会影响这些预测。Proteograph 平台仍然是重点，能够支持大规模研究并推动未来增长。</p>
<p>总之，Seer, Inc. 的财报电话会议突显了成就与挑战的结合。尽管公司在其 Proteograph 平台和战略合作伙伴关系方面取得了进展，但仍面临外部经济因素带来的障碍。前瞻性指导反映出谨慎的乐观，专注于利用其强大的财务状况和创新平台来应对未来的不确定性。</p>

SEER

<p>Seer, Inc. 举行了第三季度财报电话会议，强调了成就和挑战。公司报告称其 Proteograph 平台需求强劲，发表的论文数量创下纪录，仪器出货量增加。然而，收入增长仅为 2%，受到政府停摆和市场不确定性的影响。Seer 参与了一项股票回购计划，减少了 14% 的流通股。尽管面临挑战，公司依然保持乐观，预计全年收入将在 1700 万到 1800 万美元之间，得益于强劲的现金储备，达到 2.51 亿美元</p>

<p>Seer, Inc. ((SEER)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Seer, Inc. ((SEER)) 举行了第三季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识你的 ETF 人工智能分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> 人工智能分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> 人工智能分析师</strong> 对你关注的 ETF 的洞察。</li>
</ul>
</div><p>The recent earnings call of Seer, Inc. painted a picture of both achievements and hurdles. The company showcased strong demand for its Proteograph platform, a record number of publications, and strategic partnerships. However, the growth was modest, and challenges arose from the government shutdown and market uncertainties affecting customer budgets and sales cycles.</p>
<div class="lb-trans"><p>Seer, Inc. 最近的财报电话会议描绘了成就与挑战并存的局面。公司展示了其 Proteograph 平台的强劲需求、创纪录的出版物数量以及战略合作伙伴关系。然而，增长幅度温和，政府停摆和市场不确定性对客户预算和销售周期造成了影响。</p>
</div><h2>Record Number of Publications</h2>
<div class="lb-trans"><h2>创纪录的出版物数量</h2>
</div><p>The company achieved a milestone with a record number of third-party publications, underscoring the value of the Proteograph. This achievement further validates the platform’s performance across a variety of applications, enhancing its credibility and market position.</p>
<div class="lb-trans"><p>公司实现了创纪录的第三方出版物数量，突显了 Proteograph 的价值。这一成就进一步验证了该平台在多种应用中的表现，增强了其信誉和市场地位。</p>
</div><h2>Increased Instrument Shipments</h2>
<div class="lb-trans"><h2>仪器出货量增加</h2>
</div><p>Seer reported a significant increase in instrument shipments, nearly tripling the number shipped in the first nine months of 2025 compared to all of 2024. This surge reflects the strong demand for the Proteograph, highlighting its growing adoption in the market.</p>
<div class="lb-trans"><p>Seer 报告称仪器出货量显著增加，2025 年前九个月的出货量几乎是 2024 年全年出货量的三倍。这一激增反映了对 Proteograph 的强劲需求，突显了其在市场上的日益普及。</p>
</div><h2>Large-Scale Study with Korea University</h2>
<div class="lb-trans"><h2>与韩国大学的大规模研究</h2>
</div><p>Seer has embarked on a large-scale study with Korea University, involving 20,000 samples, alongside a 10,000-sample project with Discovery Life Sciences. These initiatives demonstrate the platform’s capability to handle extensive research projects, potentially leading to significant scientific advancements.</p>
<div class="lb-trans"><p>Seer 与韩国大学开展了一项大规模研究，涉及 20,000 个样本，同时还与 Discovery Life Sciences 开展了一个 10,000 个样本的项目。这些举措展示了该平台处理大规模研究项目的能力，可能带来重大的科学进展。</p>
</div><h2>High Customer Engagement</h2>
<div class="lb-trans"><h2>高客户参与度</h2>
</div><p>The Proteograph ONE Assay and SP200 Automation Instrument have received overwhelmingly positive feedback from customers. The strong demand and utilization observed in the initial months post-launch indicate a successful market entry and customer satisfaction.</p>
<div class="lb-trans"><p>Proteograph ONE 检测和 SP200 自动化仪器获得了客户的极大好评。发布后初期观察到的强劲需求和使用情况表明市场进入成功，客户满意度高。</p>
</div><h2>First Joint Sale with Thermo Fisher</h2>
<div class="lb-trans"><h2>与 Thermo Fisher 的首次联合销售</h2>
</div><p>The company marked progress in its collaboration with Thermo Fisher by securing the first joint sale. This development signifies a promising start to the partnership, potentially opening new avenues for growth and innovation.</p>
<div class="lb-trans"><p>公司在与 Thermo Fisher 的合作中取得了进展，成功实现了首次联合销售。这一发展标志着合作的良好开端，可能为增长和创新开辟新的途径。</p>
</div><h2>Share Repurchase Program</h2>
<div class="lb-trans"><h2>股票回购计划</h2>
</div><p>Seer has actively engaged in a share repurchase program, buying back approximately $22 million of Class A common shares. This move has reduced the net total shares outstanding by about 14%, reflecting the company’s confidence in its financial health and future prospects.</p>
<div class="lb-trans"><p>Seer 积极参与股票回购计划，回购了约 2200 万美元的 A 类普通股。这一举措使得净流通股总数减少了约 14%，反映了公司对其财务健康和未来前景的信心。</p>
</div><h2>Minimal Revenue Growth</h2>
<div class="lb-trans"><h2>收入增长微弱</h2>
</div><p>Despite the achievements, Seer reported minimal revenue growth, with a 2% year-over-year increase to $4.1 million. This modest growth highlights the challenges faced in the current economic climate, particularly due to external factors like government policies.</p>
<div class="lb-trans"><p>尽管取得了一些成就，Seer 报告称收入增长微弱，同比仅增长 2%，达到 410 万美元。这一温和增长突显了当前经济环境中面临的挑战，特别是由于外部因素如政府政策的影响。</p>
</div><h2>Challenges Due to Government Shutdown</h2>
<div class="lb-trans"><h2>政府停摆带来的挑战</h2>
</div><p>The government shutdown has posed significant challenges, contributing to uncertainty around budgets and funding availability. This situation has impacted the company’s operations and financial performance, necessitating strategic adjustments.</p>
<div class="lb-trans"><p>政府停摆带来了重大挑战，导致预算和资金可用性的不确定性。这种情况影响了公司的运营和财务表现，迫使其进行战略调整。</p>
</div><h2>Elongated Sales Cycles</h2>
<div class="lb-trans"><h2>销售周期延长</h2>
</div><p>Seer is experiencing elongated sales cycles, primarily due to pressure on CapEx budgets and the impact of the government shutdown on NIH funding. This has added complexity to the sales process, affecting revenue realization timelines.</p>
<div class="lb-trans"><p>Seer 正经历销售周期延长，主要是由于资本支出预算的压力以及政府停摆对 NIH 资金的影响。这为销售过程增加了复杂性，影响了收入实现的时间表。</p>
</div><h2>Ongoing Market Uncertainty</h2>
<div class="lb-trans"><h2>持续的市场不确定性</h2>
</div><p>The company anticipates revenue to be in the lower half of its guidance range due to ongoing market uncertainty. Government funding constraints and customer budget limitations continue to pose challenges, influencing financial projections.</p>
<div class="lb-trans"><p>由于持续的市场不确定性，公司预计收入将在指导范围的下半部分。政府资金限制和客户预算限制继续带来挑战，影响财务预测。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Seer remains optimistic about its future, despite the hurdles. The company ended the quarter with a strong balance sheet, holding approximately $251 million in cash, cash equivalents, and investments. It expects full-year revenue to range between $17 million and $18 million, although government funding uncertainties and the potential impacts of the shutdown may affect these projections. The Proteograph platform continues to be a focal point, enabling large-scale studies and driving future growth.</p>
<div class="lb-trans"><p>尽管面临挑战，Seer 对未来保持乐观。公司以强劲的资产负债表结束了本季度，持有约 2.51 亿美元的现金、现金等价物和投资。预计全年收入将在 1700 万美元到 1800 万美元之间，尽管政府资金的不确定性和停摆的潜在影响可能会影响这些预测。Proteograph 平台仍然是重点，能够支持大规模研究并推动未来增长。</p>
</div><p>In conclusion, Seer, Inc.’s earnings call highlighted a blend of accomplishments and challenges. While the company is making strides with its Proteograph platform and strategic partnerships, it faces hurdles from external economic factors. The forward-looking guidance reflects cautious optimism, with a focus on leveraging its strong financial position and innovative platform to navigate the uncertainties ahead.</p>
<div class="lb-trans"><p>总之，Seer, Inc. 的财报电话会议突显了成就与挑战的结合。尽管公司在其 Proteograph 平台和战略合作伙伴关系方面取得了进展，但仍面临外部经济因素带来的障碍。前瞻性指导反映出谨慎的乐观，专注于利用其强大的财务状况和创新平台来应对未来的不确定性。</p>
</div>

Seer, Inc. 财报电话会议：在挑战中取得的成就